James Sullivan
Equibles does not estimate personal net worth.
Get an email with a short summary when enGene Therapeutics Inc. publishes a filing, an earnings call transcript or a press release.
Get ENGN alertsAbout James Sullivan
The proxy statement of enGene Therapeutics Inc. reports total compensation of $896,242 for James Sullivan in fiscal 2023, including a base salary of $379,500. Disclosed compensation is on record for 2 fiscal years. enGene Therapeutics Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at enGene Therapeutics Inc. includes Ron Cooper (CEO and Board Member), Ronald H. W. Cooper (CEO and Board Member), Ronald H.W. Cooper (CEO and Board Member) and 7 others.
Affiliation history
-
enGene Therapeutics Inc. (ENGN)
Proxy statement
Current
Company network
Leadership on record at enGene Therapeutics Inc.
- Ron Cooper CEO, Board Member
- Ronald H. W. Cooper CEO, Board Member
- Ronald H.W. Cooper CEO, Board Member
- Ryan Daws CFO
- Alex Nichols COO
- Alexander Nichols COO
- Dr. Alex Nichols COO
- Anthony Cheung CTO
- Joan Connolly CTO
- Dr. William Grossman Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | enGene Therapeutics Inc. (ENGN) | Chief Scientific Officer | $379,500 | $896,242 |
| 2022 | enGene Therapeutics Inc. (ENGN) | Chief Scientific Officer | $279,250 | $439,866 |
Recent activity
No call appearances or filed executive changes recorded yet.